Blaming not only budget busting prices but also gargantuan portions on regular menus and other factors like shrinking ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Food choices fall into three main categories: “GLP-1 friendly” (aimed at people taking weight loss medications like ... Shipping costs aren’t included in plan pricing. The 14-day plan ...

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

Independence Blue Cross began limiting coverage of GLP-1 drugs on Jan. 1 to some medical conditions, but not obesity or weight loss.

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS ...

Obesity is an epidemic in the United States, but more people are shedding pounds with the help of weight loss drugs.

Colorado’s spending on highly effective but costly weight-loss drugs for state workers more than quadrupled from 2023 to 2024 ...

The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, ...